Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic etoricoxib 120 mg vs ARCOXIA 120 mg under fasting in healthy Thai volunteers
TCTR20180424001Phase 1Active, not recruiting
- Sponsor
- International Bio Service
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etoricoxib in pain, osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by International Bio Service. Primary endpoints: Cmax bioequivalence and AUC bioequivalence. Started Jun 2018; status: active, not recruiting.
02
Drugs
etoricoxib
03
Conditions
painosteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on TCTR20180424001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180424001.